Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus non-biologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
Conclusions: Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective option over the short-term in the investigated psoriasis population.
PMID: 31940225 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Acitretin | Belgium Health | Dermatology | Greece Health | Italy Health | Methotrexate | Netherlands Health | Portugal Health | Psoriasis | Skin | Spain Health | Taclonex